Vericel (VCEL) Competitors $57.26 +1.43 (+2.56%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VCEL vs. RGNX, KRYS, ALEC, ITOS, CCCC, PCVX, CTLT, SRPT, RVMD, and QGENShould you be buying Vericel stock or one of its competitors? The main competitors of Vericel include REGENXBIO (RGNX), Krystal Biotech (KRYS), Alector (ALEC), iTeos Therapeutics (ITOS), C4 Therapeutics (CCCC), Vaxcyte (PCVX), Catalent (CTLT), Sarepta Therapeutics (SRPT), Revolution Medicines (RVMD), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. Vericel vs. REGENXBIO Krystal Biotech Alector iTeos Therapeutics C4 Therapeutics Vaxcyte Catalent Sarepta Therapeutics Revolution Medicines Qiagen Vericel (NASDAQ:VCEL) and REGENXBIO (NASDAQ:RGNX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, community ranking, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Do insiders and institutionals hold more shares of VCEL or RGNX? 88.1% of REGENXBIO shares are held by institutional investors. 5.2% of Vericel shares are held by company insiders. Comparatively, 13.1% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer VCEL or RGNX? In the previous week, REGENXBIO had 7 more articles in the media than Vericel. MarketBeat recorded 16 mentions for REGENXBIO and 9 mentions for Vericel. Vericel's average media sentiment score of 0.70 beat REGENXBIO's score of 0.35 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive REGENXBIO 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in VCEL or RGNX? REGENXBIO received 88 more outperform votes than Vericel when rated by MarketBeat users. Likewise, 65.86% of users gave REGENXBIO an outperform vote while only 61.68% of users gave Vericel an outperform vote. CompanyUnderperformOutperformVericelOutperform Votes34661.68% Underperform Votes21538.32% REGENXBIOOutperform Votes43465.86% Underperform Votes22534.14% Is VCEL or RGNX more profitable? Vericel has a net margin of 1.56% compared to REGENXBIO's net margin of -283.19%. Vericel's return on equity of 1.48% beat REGENXBIO's return on equity.Company Net Margins Return on Equity Return on Assets Vericel1.56% 1.48% 0.96% REGENXBIO -283.19%-70.65%-41.68% Which has higher earnings and valuation, VCEL or RGNX? Vericel has higher revenue and earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVericel$226.84M12.46-$3.18M$0.06954.33REGENXBIO$90.24M5.29-$263.49M-$5.03-1.91 Do analysts rate VCEL or RGNX? Vericel currently has a consensus price target of $58.14, suggesting a potential upside of 1.54%. REGENXBIO has a consensus price target of $35.64, suggesting a potential upside of 270.06%. Given REGENXBIO's higher probable upside, analysts clearly believe REGENXBIO is more favorable than Vericel.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vericel 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00REGENXBIO 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92 Which has more volatility & risk, VCEL or RGNX? Vericel has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. SummaryVericel beats REGENXBIO on 11 of the 18 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Vericel News Delivered to You Automatically Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCEL vs. The Competition Export to ExcelMetricVericelBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.76B$2.94B$5.05B$8.87BDividend YieldN/A1.89%4.97%4.06%P/E Ratio954.4921.3797.3414.18Price / Sales12.46382.101,218.4289.42Price / Cash2,978.10160.1133.5132.79Price / Book12.114.195.805.12Net Income-$3.18M-$41.63M$119.07M$225.99M7 Day Performance8.57%-4.73%-1.83%-1.32%1 Month Performance39.05%-6.53%-3.64%0.60%1 Year Performance59.59%25.63%31.62%26.23% Vericel Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCELVericel1.0623 of 5 stars$57.26+2.6%$58.14+1.5%+56.1%$2.76B$226.84M954.49300Analyst ForecastRGNXREGENXBIO4.4242 of 5 stars$9.63+0.7%$35.64+270.1%-51.9%$473.65M$90.24M0.00344Analyst ForecastKRYSKrystal Biotech4.8348 of 5 stars$178.10+0.1%$202.29+13.6%+70.0%$5.12B$50.70M100.62229Positive NewsALECAlector4.4456 of 5 stars$3.64-5.7%$20.67+468.5%-26.1%$355.99M$61.51M-2.23270Positive NewsITOSiTeos Therapeutics3.4955 of 5 stars$7.85-0.6%$31.50+301.3%-23.0%$288.62M$12.60M0.0090CCCCC4 Therapeutics2.6434 of 5 stars$4.05-2.4%$10.00+146.9%+139.6%$285.89M$33.67M-2.38150Analyst ForecastPCVXVaxcyte3.2906 of 5 stars$85.96-1.3%$147.50+71.6%+67.2%$10.85BN/A0.00160CTLTCatalent3.03 of 5 stars$59.00+0.2%$63.40+7.5%+47.8%$10.71B$4.38B-26.1116,900SRPTSarepta Therapeutics4.9373 of 5 stars$110.86+4.0%$181.33+63.6%+33.5%$10.18B$1.64B88.691,314Analyst DowngradeGap UpRVMDRevolution Medicines2.7869 of 5 stars$57.07+1.1%$61.00+6.9%+162.6%$9.50B$11.58M0.00443QGENQiagen4.4347 of 5 stars$42.11+3.2%$50.88+20.8%+2.5%$9.31B$1.97B107.975,967Positive NewsHigh Trading Volume Related Companies and Tools Related Companies RGNX Competitors KRYS Competitors ALEC Competitors ITOS Competitors CCCC Competitors PCVX Competitors CTLT Competitors SRPT Competitors RVMD Competitors QGEN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VCEL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VCEL Stock Alerts